Non-Valvular Atrial Fibrillation Clinical Trial
Official title:
A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure
This is a single arm, open label, single site study assessing the feasibility of post-procedural edoxaban therapy in atrial fibrillation (AF) patients after clinically indicated WATCHMAN left atrial appendage (LAA) closure.
Status | Recruiting |
Enrollment | 75 |
Est. completion date | December 31, 2019 |
Est. primary completion date | November 30, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - The patient has documented paroxysmal, persistent, or permanent non-valvular AF (i.e., the patient has not been diagnosed with rheumatic mitral valve disease). - LAA closure with the WATCHMAN device is planned - The patient fulfills the FDA indication for WATCHMAN LAA closure - The patient or legal representative is able to understand and willing to provide written informed consent to participate in the trial - The patient is able and willing to return for required follow-up visits and examinations. - The patient is 18 years of age or older Exclusion Criteria: - Conditions other than atrial fibrillation that require anti-coagulation (e.g., a prosthetic heart valve) - Stroke within the previous 7 days - Hypersensitivity to edoxaban - Moderate or severe mitral stenosis - A need for aspirin at a dose of >81 mg a day - A need for on-going treatment with dual antiplatelet therapy with aspirin and clopidogrel - A need for on-going treatment with ticagrelor or prasugrel - No LAA closure device implanted during procedure - Procedural complication of LAA closure (e.g., stroke, systemic embolism, bleeding, vascular complication [e.g., groin hematoma >10cm, AV fistula, or pseudoaneurysm), or serious pericardial effusion) - Planned surgery or invasive procedure within 6±2 weeks of enrollment |
Country | Name | City | State |
---|---|---|---|
United States | Scripps Health | La Jolla | California |
Lead Sponsor | Collaborator |
---|---|
Scripps Health | Daiichi Sankyo Inc. |
United States,
ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Pfeffer M, Hohnloser S, Yusuf S. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006 Jun 10;367(9526):1903-12. — View Citation
Bösche LI, Afshari F, Schöne D, Ewers A, Mügge A, Gotzmann M. Initial Experience With Novel Oral Anticoagulants During the First 45 Days After Left Atrial Appendage Closure With the Watchman Device. Clin Cardiol. 2015 Dec;38(12):720-4. doi: 10.1002/clc.22478. Epub 2015 Oct 14. — View Citation
Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O'Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011 Mar 3;364(9):806-17. doi: 10.1056/NEJMoa1007432. Epub 2011 Feb 10. — View Citation
Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M, Ezekowitz M, Oldgren J, Eikelboom JW, Reilly PA, Yusuf S. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation. 2013 Feb 5;127(5):634-40. doi: 10.1161/CIRCULATIONAHA.112.115386. Epub 2012 Dec 27. — View Citation
Lamberts M, Gislason GH, Lip GY, Lassen JF, Olesen JB, Mikkelsen AP, Sørensen R, Køber L, Torp-Pedersen C, Hansen ML. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation. 2014 Apr 15;129(15):1577-85. doi: 10.1161/CIRCULATIONAHA.113.004834. Epub 2014 Jan 27. — View Citation
Lopes RD, Al-Khatib SM, Wallentin L, Yang H, Ansell J, Bahit MC, De Caterina R, Dorian P, Easton JD, Erol C, Ezekowitz JA, Gersh BJ, Granger CB, Hohnloser SH, Horowitz J, Hylek EM, McMurray JJ, Mohan P, Vinereanu D, Alexander JH. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet. 2012 Nov 17;380(9855):1749-58. doi: 10.1016/S0140-6736(12)60986-6. Epub 2012 Oct 2. Erratum in: Lancet. 2013 Jan 19;381(9862):204. — View Citation
Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011 Jun 14;123(23):2736-47. doi: 10.1161/CIRCULATIONAHA.110.009449. — View Citation
Price MJ, Holmes DR. Mechanical closure devices for atrial fibrillation. Trends Cardiovasc Med. 2014 Aug;24(6):225-31. doi: 10.1016/j.tcm.2014.06.001. Epub 2014 Jun 8. Review. — View Citation
Price MJ, Reddy VY, Valderrábano M, Halperin JL, Gibson DN, Gordon N, Huber KC, Holmes DR Jr. Bleeding Outcomes After Left Atrial Appendage Closure Compared With Long-Term Warfarin: A Pooled, Patient-Level Analysis of the WATCHMAN Randomized Trial Experience. JACC Cardiovasc Interv. 2015 Dec 28;8(15):1925-32. doi: 10.1016/j.jcin.2015.08.035. Epub 2015 Nov 25. — View Citation
Price MJ, Valderrábano M. Left atrial appendage closure to prevent stroke in patients with atrial fibrillation. Circulation. 2014 Jul 8;130(2):202-12. doi: 10.1161/CIRCULATIONAHA.114.009060. Review. — View Citation
Price MJ. Left atrial appendage occlusion with the WATCHMAN™ for stroke prevention in atrial fibrillation. Rev Cardiovasc Med. 2014;15(2):142-51. Review. — View Citation
Reddy VY, Möbius-Winkler S, Miller MA, Neuzil P, Schuler G, Wiebe J, Sick P, Sievert H. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol. 2013 Jun 25;61(25):2551-6. doi: 10.1016/j.jacc.2013.03.035. Epub 2013 Apr 10. — View Citation
Xu H, Ruff CT, Giugliano RP, Murphy SA, Nordio F, Patel I, Shi M, Mercuri M, Antman EM, Braunwald E. Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 Trial. J Am Heart Assoc. 2016 Feb 23;5(2). pii: e002587. doi: 10.1161/JAHA.115.002587. — View Citation
* Note: There are 13 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Death, stroke, systemic embolism or GUSTO outcomes | Composite of death, stroke, systemic embolism, or GUSTO moderate/severe bleeding will be collected at 6 weeks post-WATCHMAN LAA closure | 6 weeks | |
Secondary | Death, stroke, or systematic embolism outcomes | Composite of death, stroke, or systemic embolism at 6 weeks and 6 months | 6 weeks and 6 months | |
Secondary | Death, stroke, or systematic embolism or GUSTO outcomes | Composite of death, stroke, systemic embolism or GUSTO moderate/severe bleeding at 6 months | 6 months | |
Secondary | Device thrombus oucomes | TEE-confirmed device thrombus (according to core laboratory) at 6 weeks | 6 weeks | |
Secondary | TEE peri-device flow outcomes | Rate of peri-device flow >=5mm at 6 week follow-up TEE | 6 weeks | |
Secondary | GUSTO mild, moderate, severe, and GUSTO moderate/severe bleeding outcomes | Individual endpoints of GUSTO mild, moderate, severe, and GUSTO moderate/severe bleeding at 6 weeks and 6 months | 6 weeks and 6 months | |
Secondary | Premature discontinuation rate of study drug | Premature discontinuation rate of study drug before 6-week visit | 6 weeks | |
Secondary | Bleeding outcomes | Bleeding according to the months Bleeding Academic Research Consortium (BARC) criteria at 6 weeks and 6 months | 6 weeks and 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02502396 -
Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
|
||
Withdrawn |
NCT03508258 -
Study to Describe Risk of Bleeding in Patients Depending on the Different Anticoagulant Therapy They Are on for Atrial Fibrillation (AF)
|
||
Terminated |
NCT03715725 -
A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients.
|
||
Active, not recruiting |
NCT05565599 -
An Early Feasibility Study Evaluating the Safety and Efficacy of the Laminar Left Atrial Appendage Closure System in Subjects With Non-Valvular Atrial Fibrillation
|
N/A | |
Completed |
NCT02756481 -
Local Adaptation of Cost Effectiveness Model for Apixaban Atrial Fibrillation Indication - Venezuela
|
N/A | |
Completed |
NCT04193826 -
The Conformal Prague Study
|
N/A | |
Completed |
NCT01884350 -
Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)
|
Phase 4 | |
Completed |
NCT02422602 -
Better Adherence With New Oral Anticoagulant in Atrial Fibrillation : Effectiveness of a Personalized Education Program
|
N/A | |
Recruiting |
NCT02147444 -
Evaluation of Effectiveness and Safety of Xa Inhibitor for the Prevention of Stroke And Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-valvular Atrial Fibrillation
|
N/A | |
Completed |
NCT01857622 -
Safety and Pharmacokinetics Study of DU-176b Administered to Non-valvular Atrial Fibrillation With Severe Renal Impairment
|
Phase 3 | |
Recruiting |
NCT04829929 -
Evaluation od Safety and Performance of the Omega™ LAA (Left Atrial Appendage) Occluder and Omega™ Delivery System in Patients With Non-Valvular Atrial Fibrillation and High Bleeding Risk
|
N/A | |
Recruiting |
NCT05761704 -
Exploratory Observation of Two Short-term Regimens After LAA Occlusion by LAMax LAAC® Device for Subjects With Non-valvular Atrial Fibrillation
|
N/A | |
Recruiting |
NCT04559243 -
Left Atrial Appendage Closure as Secondary Prevention of Atrial Fibrillation-related Embolic Events
|
||
Completed |
NCT03570047 -
Safety and Effectiveness of Oral Anticoagulants in Patients With Non-valvular Atrial Fibrillation
|
||
Terminated |
NCT03204695 -
WAVECREST Post Market Clinical Follow-Up (PMCF) Study
|
N/A | |
Completed |
NCT04722679 -
A Study to Collect Information on the Characteristics of Elderly Belgian Patients With NVAF That Are Treated With a NOAC for This Indication With a Special Focus on Their Fear of Bleeding While Using a NOAC vs the Clinical Benefit of a NOAC of Thrombosis/Stroke Prevention.
|
||
Completed |
NCT04297072 -
Study to Gather Information on the Kidney Function of Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem) Treated With Rivaroxaban or Vitamin K Antagonists
|
||
Recruiting |
NCT05320627 -
Population Pharmacokinetics of Edoxaban in Chinese Patients With Non-Valvular Atrial Fibrillation
|
Phase 4 | |
Completed |
NCT04519944 -
Edoxaban in Patients With Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
|
||
Completed |
NCT02488421 -
Real Evidence of Anticoagulation Treatment in Non-valvular Atrial Fibrillation in Germany, UK and France: REACT-AF2
|
N/A |